SYRS Syros Pharmaceuticals, Inc. Insider Trading

CEO Chee Conley bought 100,000 shares (100.0K shares) for $160,680.00 at blended $1.61; stock down 80.0% from 52-week high.

Chee Conley, the President & CEO, executed 2 purchases totaling 100,000 shares for $160,680.00 between September 10–11, 2024, raising his holdings from 22,504 shares to 122,504 shares (+444.4%). The timing occurs after the stock has declined 80.0% from its 52-week high of $7.84 and is trading 18.2% lower over the past 30 days and 73.8% lower over 90 days. Syros remains unprofitable with net income of $-23,327,000.00 on quarterly revenue of $3,762,000.00 and faces a contraction headwind (annual revenue growth of -33.2%). The scale of the purchase—more than quadrupling the CEO's pre-transaction stake—during a period of steep price decline and operational losses suggests management is materially increasing exposure at a depressed valuation in its own stock.

Syros CFO Haas bought 100,000 shares in 3 transactions totaling $161,239.79 on Sept 10-12.

Jason Haas, Chief Financial Officer of Syros Pharmaceuticals, completed 3 separate purchases totaling 100,000 shares for $161,239.79 between September 10-12, 2024, increasing his holdings from 24,552 shares to 124,552 shares (+407.3%). The blended average purchase price was $1.61, while the stock now trades at $1.57 (current price), down 80.0% from its 52-week high of $7.84 and down 73.8% over the past 90 days. The underlying business context reflects significant stress: the company generated only $3.8M in quarterly revenue, posted a net loss of $23.3M, contracted 33.2% year-over-year in annual revenue, and carries a market cap of $42.0M while remaining unprofitable. A senior executive accumulating a material stake during a steep drawdown and deteriorating operational backdrop warrants investor scrutiny of the transaction rationale.